Reunion Neuroscience Inc

Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Company Adds Former Executive at Takeda, Pfizer, AstraZeneca, GSK and Merck to Leadership Team Company Adds Former Executive at Takeda, Pfizer, AstraZeneca, GSK and Merck to Leadership Team

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

First-in-Human Findings Highlight RE104's Strong Safety and Differentiated Pharmacodynamic Profile, Setting Stage for Initiation of Phase 2 Development in Postpartum Depression First-in-Human Findings Highlight RE104's Strong Safety and Differentiated Pharmacodynamic Profile, Setting Stage for Initiation of Phase 2 Development in Postpartum Depression

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Company Plans to Report Phase 1 Interim Analysis for RE104 in Q1 2023 and Include Data Differentiating its Safety, Tolerability and Pharmacodynamic Profile from Other Psychedelics in Clinical Development

Reunion Neuroscience Inc. Provides 2023 Corporate Update

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today announced that it has entered into an equity distribution agreement with Canaccord Genuity to establish an at-the-market equity facility.

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

Reunion Neuroscience, Inc. (NASDAQ:REUN ) Q2 2023 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Phil Carlson - IR, MD, KCSA Strategic Communications Greg Mayes - President and CEO Edward Smith - CFO Nathan Bryson - Chief Scientific Officer Conference Call Participants Andrew Partheniou - Stifel Patrick Trucchio - H.C. Wainwright Antonia Borovina - Bloom Burton & Co. Michael Okunewitch - Maxim Operator Greetings, and welcome to Reunion Neuroscience Fiscal Second Quarter '23 Earnings Call.

Reunion Neuroscience, Inc. (REUN) Q2 2023 Earnings Call Transcript

TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported its business update and fiscal second quarter ended September 30, 2022 results.

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

TORONTO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that it plans to release its business update and financial results for its fiscal 2023 second quarter ended September 30, 2022, before market open on Monday, November 14, 2022.

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

TORONTO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) ("Reunion" or the “Company”), a biopharmaceutical company committed to developing innovative therapeutic solutions for underserved mental health conditions, announced today that the Company will participate in two upcoming conferences in November.

Reunion Neuroscience to Present at Upcoming November Conferences

Company Continues to Deepen Executive Bench with Life Science Industry Veterans Company Continues to Deepen Executive Bench with Life Science Industry Veterans

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

“Raising Capital for Psychedelic Endeavors” Panel Part of Conference's Psychedelic Business Forum “Raising Capital for Psychedelic Endeavors” Panel Part of Conference's Psychedelic Business Forum

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

TORONTO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”), a leader in novel psychedelic drug development committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds, today announced that Ronan Levy has resigned as Director of the Company and Paula Amy Hewitt has resigned as General Counsel & Corporate Secretary, effective October 7, 2022.

Reunion Neuroscience Inc. Announces Executive Changes

TORONTO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced that management will participate in the Cantor Neurology & Psychiatry Conference taking place on October 6-7, 2022 at the Ritz Carlton, San Francisco.

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) ("Reunion" or the “Company”) today announced the results of the votes held at its September 29, 2022 Annual General and Special Meeting of shareholders (the “Meeting”).

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting

Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer

TORONTO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative psychedelic-inspired therapeutics for improved mental health outcomes, today announced it will participate in two upcoming investor conferences in September 2022.

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) ("Reunion"), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled its 2022 Annual General Meeting of Shareholders for September 29, 2022 at 10:00 AM ET.

News for Reunion Neuroscience Inc Stock (REUN)